$CRSP

Shares of gene-editing companies, including Prime Medicine (PRME), Beam Therapeutics, Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and CRISPR Therapeutics (CRSP), rose after the FDA issued draft guidance to expedite personalized treatments for rare genetic diseases. The new approach allows one application for multiple versions of the same gene-editing treatment. PRME gained 20%, with other companies seeing 4-14% increases.

CRISPR Therapeutics (CRSP) reports promising Phase 1a trial data for CTX310, a gene-editing therapy for high LDL and TG levels, with potential market of 40M+ U.S. patients. The company also shares Casgevy's rights with Vertex (VRTX). CTX310's Phase 1b results are expected in November. CRISPR's pipeline includes other candidates like CTX611, but faces risks of setbacks and market adoption challenges.

CRISPR Therapeutics CEO Samarth Kulkarni sold 47,837 shares at $49.78 each, totaling $2.38M. He now owns 311,899 shares. The sale covered taxes on vested restricted stock units, according to an SEC filing.

Kulkarni Samarth (Chief Executive Officer) sold 47,837 shares of CRISPR Therapeutics AG (CRSP) at $49.78 ($2.38M total) on 2026-10-19.

CRISPR Therapeutics AG (CRSP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. a) Appointment of New Chief Financial Officer Appointment of Andrew J. Silver as Chief Financial Officer On October 19, 20

CRISPR Therapeutics (CRSP) announced Raju Prasad will step down as CFO to pursue external opportunities. A.J. Silver, Senior Vice President of Finance, will succeed him. Prasad praised the company's progress and Silver's experience. CRISPR Therapeutics develops gene-based medicines and recently approved its first CRISPR-based therapy, CASGEVY.

Cathie Wood's Ark Invest bought $3.4 million of CRISPR Therapeutics (CRSP) stock over two days. CRISPR's Casgevy, a gene-editing therapy, generated $76M in Q2 revenue, up 151% YoY. The company is developing CTX-310 for heart disease and CTX611 for blood clots, with a phase 2 trial readout expected this year.

Insiders at PepsiCo (PEP), Costco (COST), BlackBerry (BB), CRISPR Therapeutics (CRSP), MicroStrategy (MSTR), GameStop (GME), and Innovative Industrial Properties (IIPR) made notable share transactions between October 12 and 16. Key transactions included PEP director Robert Pohlad buying 184,646 shares for ~$23.69M and GME CEO Ryan Cohen purchasing 844,130 shares for ~$22.77M.

George Simeon sold 14,514 shares of CRISPR Therapeutics AG (CRSP) at $49.63 ($0.72M total) on 2026-10-14 under a Rule 10b5-1 trading plan.

Kulkarni Samarth (Chief Executive Officer) sold 4,098 shares of CRISPR Therapeutics AG (CRSP) at $49.26 ($0.20M total) on 2026-10-14.